Biologic therapy in lupus nephritis.
This position paper critically analyzes the available controlled data regarding biologic therapy in lupus nephritis (LN). Rather than an exhaustive review of all published evidence, the stress is put on the unmet medical needs in LN, the design of trials aimed at testing the effect of a biologic in LN, the possible reasons for LN trial failures and the future of biological therapy in LN.
Department of Rheumatology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Bruxelles, Belgique.
Frédéric A
FA
Houssiau
D001688:Biological Products / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005544:Forecasting; D006301:Health Services Needs and Demand; D006801:Humans; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000276:immunology; D012107:Research Design
D001688:Biological Products